Thank you for Subscribing to Life Science Review Weekly Brief
The acquisition results in an innovative, market-leading analytics platform that offers on-demand insights across dozens of normalized real-world evidence and market access data sets to aid in decision-making throughout the pipeline and prescription process.
FREMONT, CA: “MMIT/Evaluate and Panalgo share a vision of generating evidence and insights faster, all to help patients get timely access to lifesaving therapies. The addition of Panalgo fits perfectly into our strategy of building a best-in-breed technology and services-driven healthcare business servicing pharma, biotech and beyond,” states MMIT CEO Mike Gallup. Managed Markets Insight & Technology (MMIT) and Evaluate, a Welsh, Carson, Anderson & Stowe, and Hg portfolio company, which merged last month to form a $1.6 billion global provider of pharmaceutical commercial intelligence confirm the acquisition of Panalgo, a premier healthcare data analytics company that serves many of the world’s largest biopharmaceutical, medical device, and contract research organizations
MMIT and Evaluate hope to change the process of bringing pharmaceuticals to market with this acquisition.
By integrating Panalgos’ flagship Instant Health Data (IHD) software, MMIT and Evaluate will provide customers with an end-to-end commercialization platform that quickly gives vital, data-driven insights, enabling life sciences professionals to make smarter decisions faster.
“The ability to quickly generate insights, inform decisions on the effectiveness and safety of new treatments, and reduce barriers to accessing care, all fulfill a huge need in the marketplace,” says Panalgo CEO Joseph Menzin, Ph.D. “With Panalgo’s best-in-class platform, MMITs expansive base of over 1,300 biopharma and payer customers, and its gold-standard formulary data, we are well-equipped to support clients from end to end.”
Jordan Menzin, CTO, will succeed Joseph Menzin as CEO of Panalgo on Nov. 1, 2021. Panalgo will continue to operate under its brand and offer cutting-edge IHD software and superior customer service.
“I’m excited to lead this next phase of Panalgo’s growth,” says Jordan Menzin. “Together, we’ll help clients solve problems by leveraging quicker, more efficient insights and, ultimately, get therapies into the hands of the patients who need them.”